The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
New Horizons for Precision Medicine in Biliary Tract Cancers
Open accessAbstract
Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-prognosis and low-incidence cancers, although the incidence of intrahepatic cholangiocarcinoma is rising. A minority of patients present with resectable disease but relapse rates are high; benefit from adjuvant capecitabine chemotherapy has been demonstrated. Cisplatin/gemcitabine combination chemotherapy has emerged as the reference first-line treatment regimen; there is no standard second-line therapy. Selected patients may be suitable for liver-directed therapy (e.g., radioembolization or external beam radiation), pending confirmation of benefit in randomized studies. Initial trials targeting the epithelial growth factor receptor and angiogenesis pathways have failed to deliver new treatments. Emerging data from next-generation sequencing analyses have identified actionable mutations (e.g., FGFR fusion rearrangements and IDH1 and IDH2 mutations), with several targeted drugs entering clinical development with encouraging results. The role of systemic therapies, including targeted therapies and immunotherapy for BTC, is rapidly evolving and is the subject of this review. Significance: The authors address genetic drivers and molecular biology from a translational perspective, in an intent to offer a clear view of the recent past, present, and future of BTC. The review describes a state-of-the-art update of the current status and future directions of research and therapy in advanced BTC. Cancer Discov; 7(9); 943–62. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Mutational load is known to be high in tumors in which immunotherapies have been shown to be effective, such as melanoma and lung cancer (223).”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Self-citationCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 1×
“These proteins are key components of the axon guidance signaling and have been recently implicated in pancreatic adenocarcinoma (71).”
BackgroundVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“In a recent phase II basket study of vemurafenib in BRAFV600-mutated non-melanoma cancers, one patient with cholangiocarcinoma achieved a durable partial response of over a year (203).”
BackgroundCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,300
Genomic spectra of biliary tract cancer
Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,284
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Wang, Y., Li, J., Xia, Y., Gong, R., Wang, K., Yan, Z., Wan, X., Liu, G., Wu, D., Shi, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.5984 · Cited by 1,057
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
BAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959
Risk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
Endo, I., Gonen, M., Yopp, A. C., Dalal, K. M., Zhou, Q., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Fong, Y., Schwartz, L., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176c4d3 · Cited by 865
Kadoch, C., & Crabtree, G. R. (2015) · Science Advances · doi:10.1126/sciadv.1500447 · Cited by 828
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., Nagino, M., Kondo, S., Nagaoka, S., Funai, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605779 · Cited by 744
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Self-citationBott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
The Genetic Landscape of the Childhood Cancer Medulloblastoma
Parsons, D. W., Li, M., Zhang, X., Jones, S., Leary, R. J., Lin, J. C.-H., Boca, S. M., Carter, H., Samayoa, J., Bettegowda, C., et al. (2011) · Science · doi:10.1126/science.1198056 · Cited by 717
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684
Georges, G. T., Nájera, O., Sowers, K., & Sowers, J. R. (2017) · Cardiorenal Medicine · doi:10.1159/000449476 · Cited by 680
Phosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., & Cobb, M. H. (1998) · Cell · doi:10.1016/s0092-8674(00)81189-7 · Cited by 677
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
Self-citationUse of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
Self-citationNTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601
Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Sole, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 575
Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Self-citationCholangiocarcinomas can originate from hepatocytes in mice
Fan, B., Malato, Y., Calvisi, D. F., Naqvi, S., Razumilava, N., Ribback, S., Gores, G. J., Dombrowski, F., Evert, M., Chen, X., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63212 · Cited by 529
Chan-on, W., Nairismägi, M.-L., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 497
Exome sequencing of liver fluke–associated cholangiocarcinoma
Ong, C. K., Subimerb, C., Pairojkul, C., Wongkham, S., Cutcutache, I., Yu, W., McPherson, J. R., Allen, G. E., Ng, C. C. Y., Wong, B. H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2273 · Cited by 486
Lee, J., Park, S. H., Chang, H.-M., Kim, J. S., Choi, H. J., Lee, M. A., Chang, J. S., Jeung, H. C., Kang, J. H., Lee, H. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70301-1 · Cited by 478
Hong, T. S., Wo, J. Y., Yeap, B. Y., Ben-Josef, E., McDonnell, E. I., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2710 · Cited by 472
Self-citationChemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
Eckel, F., & Schmid, R. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603648 · Cited by 464
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornella, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460
Self-citationRoss, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
Li, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., Liu, C., Shen, B., Wang, X.-A., Wu, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3030 · Cited by 443
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
Biliary cancer: Utility of next‐generation sequencing for clinical management
Javle, M., Bekaii‐Saab, T., Jain, A., Wang, Y., Kelley, R. K., Wang, K., Kang, H. C., Catenacci, D., Ali, S., Krishnan, S., et al. (2016) · Cancer · doi:10.1002/cncr.30254 · Cited by 418
Malka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardière, C., Boucher, E., Fartoux, L., Faivre, S., Blanc, J.-F., Viret, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70212-8 · Cited by 408
How Fibroblast Growth Factor 23 Works
Liu, S., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010068 · Cited by 408
Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., Hirohashi, S., & Shibata, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604129 · Cited by 404
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes
Sekiya, S., & Suzuki, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63065 · Cited by 348
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 344
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Second-line chemotherapy in advanced biliary cancer: a systematic review
Lamarca, A., Hubner, R. A., David Ryder, W., & Valle, J. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu162 · Cited by 339
Self-citationPhase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3579 · Cited by 318
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., Murphy, S. J., McWilliams, R. R., Hart, S. N., Halling, K. C., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 313
Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 311
Tao, R., Krishnan, S., Bhosale, P. R., Javle, M. M., Aloia, T. A., Shroff, R. T., Kaseb, A. O., Bishop, A. J., Swanick, C. W., Koay, E. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.3778 · Cited by 309
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307
Zhu, A. X., Meyerhardt, J. A., Blaszkowsky, L. S., Kambadakone, A. R., Muzikansky, A., Zheng, H., Clark, J. W., Abrams, T. A., Chan, J. A., Enzinger, P. C., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70333-x · Cited by 303
Self-citationMulti-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303
Zatonski, W. A., Przewozniak, K., Lowenfels, A. B., Boyle, P., Maisonneuve, P., Bueno de Mesquita, H. B., Moerman, C. J., Ghadirian, P., Simard, A., Jain, M., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1132 · Cited by 286
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H.-J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., Duggan, M., Cunningham, D., Anthoney, D. A., Corrie, P., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00139-4 · Cited by 273
Self-citationLubner, S. J., Mahoney, M. R., Kolesar, J. L., LoConte, N. K., Kim, G. P., Pitot, H. C., Philip, P. A., Picus, J., Yong, W.-P., Horvath, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4075 · Cited by 267
Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation
Ferby, I., Reschke, M., Kudlacek, O., Knyazev, P., Pantè, G., Amann, K., Sommergruber, W., Kraut, N., Ullrich, A., Fässler, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1401 · Cited by 263
Gruenberger, B., Schueller, J., Heubrandtner, U., Wrba, F., Tamandl, D., Kaczirek, K., Roka, R., Freimann-Pircher, S., & Gruenberger, T. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70247-3 · Cited by 247
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Barr Fritcher, E. G., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 244
Risk factors for biliary tract carcinogenesis
Chapman, R. W. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s308 · Cited by 244
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
Sia, D., Tovar, V, Moeini, A., & Llovet, J. M. (2013) · Oncogene · doi:10.1038/onc.2012.617 · Cited by 235
Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005) · The Journal of Pathology · doi:10.1002/path.1779 · Cited by 234
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse
Kalamarides, M., Niwa-Kawakita, M., Leblois, H., Abramowski, V., Perricaudet, M., Janin, A., Thomas, G., Gutmann, D. H., & Giovannini, M. (2002) · Genes & Development · doi:10.1101/gad.226302 · Cited by 224
Nomogram for Predicting the Benefit of Adjuvant Chemoradiotherapy for Resected Gallbladder Cancer
Wang, S. J., Lemieux, A., Kalpathy-Cramer, J., Ord, C. B., Walker, G. V., Fuller, C. D., Kim, J.-S., & Thomas, C. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8020 · Cited by 217
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
Bengala, C., Bertolini, F., Malavasi, N., Boni, C., Aitini, E., Dealis, C., Zironi, S., Depenni, R., Fontana, A., Del Giovane, C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605458 · Cited by 216
Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Mertens, J. C., Fingas, C. D., Christensen, J. D., Smoot, R. L., Bronk, S. F., Werneburg, N. W., Gustafson, M. P., Dietz, A. B., Roberts, L. R., Sirica, A. E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2130 · Cited by 212
Galdy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N., & Valle, J. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9645-x · Cited by 209
Self-citationXu, X. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27282 · Cited by 207
Enhanced Self-Renewal Capability in Hepatic Stem/Progenitor Cells Drives Cancer Initiation
Chiba, T., Zheng, Y.-W., Kita, K., Yokosuka, O., Saisho, H., Onodera, M., Miyoshi, H., Nakano, M., Zen, Y., Nakanuma, Y., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.016 · Cited by 204
A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas
Zender, S., Nickeleit, I., Wuestefeld, T., Sörensen, I., Dauch, D., Bozko, P., El-Khatib, M., Geffers, R., Bektas, H., Manns, M. P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.019 · Cited by 200
Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria
Deng, Y., & Wu, X. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.12050 · Cited by 194
KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma
O'Dell, M. R., Li Huang, J., Whitney-Miller, C. L., Deshpande, V., Rothberg, P., Grose, V., Rossi, R. M., Zhu, A. X., Land, H., Bardeesy, N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3596 · Cited by 192
Self-citationAdjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Primrose, J. N., Fox, R., Palmer, D. H., Prasad, R., Mirza, D., Anthoney, D. A., Corrie, P., Falk, S., Wasan, H. S., Ross, P. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4006 · Cited by 190
Self-citationLepisto, A. J., Moser, A. J., Zeh, H. J., Lee, K., Bartlett, D. L., McKolanis, J., Geller, B. A., Schmotzer, A. R., Potter, D. P., Whiteside, T. L., et al. (2008) · PubMed · Cited by 189
Al-Adra, D. P., Gill, R. S., Axford, S. J., Shi, X., Kneteman, N., & Liau, S.-S. (2015) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.09.007 · Cited by 187
Benckert, C., Jonas, S., Cramer, T., von Marschall, Z., Schäfer, G., Peters, M., Wagner, K., Radke, C., Wiedenmann, B., Neuhaus, P., et al. (2003) · PubMed · Cited by 185
Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
Brand, M., Measures, A. M., Wilson, B. G., Cortopassi, W. A., Alexander, R., Höss, M., Hewings, D. S., Rooney, T. P. C., Paton, R. S., & Conway, S. J. (2015) · ACS Chemical Biology · doi:10.1021/cb500996u · Cited by 172
Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma
Leone, F., Cavalloni, G., Pignochino, Y., Sarotto, I., Ferraris, R., Piacibello, W., Venesio, T., Capussotti, L., Risio, M., & Aglietta, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1692 · Cited by 170
Dal Molin, M., Matthaei, H., Wu, J., Blackford, A., Debeljak, M., Rezaee, N., Wolfgang, C. L., Butturini, G., Salvia, R., Bassi, C., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3096-1 · Cited by 169
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Silva, V. W. K., Askan, G., Daniel, T. D., Lowery, M., Klimstra, D. S., Abou-Alfa, G. K., & Shia, J. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.10.04 · Cited by 169
Gourgiotis, S., Kocher, H. M., Solaini, L., Yarollahi, A., Tsiambas, E., & Salemis, N. S. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.11.011 · Cited by 169
Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells
Fingas, C. D., Bronk, S. F., Werneburg, N. W., Mott, J. L., Guicciardi, M. E., Cazanave, S. C., Mertens, J. C., Sirica, A. E., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.24588 · Cited by 163
Conferring specificity on the ubiquitous Raf/MEK signalling pathway
O'Neill, E., & Kolch, W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601488 · Cited by 162
Chaiyadet, S., Sotillo, J., Smout, M., Cantacessi, C., Jones, M. K., Johnson, M. S., Turnbull, L., Whitchurch, C. B., Potriquet, J., Laohaviroj, M., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv291 · Cited by 160
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160
Self-citationPorcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3 -mutant neoplasia
Koo, B.-K., van Es, J. H., van den Born, M., & Clevers, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508113112 · Cited by 158
Surgery for cholangiocarcinoma: the role of liver transplantation
Rosen, C. B., Heimbach, J. K., & Gores, G. J. (2008) · HPB · doi:10.1080/13651820801992542 · Cited by 158
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 152
Self-citationBang, Y., Doi, T., de Braud, F., Piha-Paul, S. A., Hollebecque, A., Razak, A. R. A., Lin, C., Ott, P., He, A. R., Yuan, S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30326-4 · Cited by 145
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
Voss, J. S., Holtegaard, L. M., Kerr, S. E., Fritcher, E. G. B., Roberts, L. R., Gores, G. J., Zhang, J., Highsmith, W. E., Halling, K. C., & Kipp, B. R. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.11.006 · Cited by 143
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 142
Self-citationLeone, F., Marino, D., Cereda, S., Filippi, R., Belli, C., Spadi, R., Nasti, G., Montano, M., Amatu, A., Aprile, G., et al. (2015) · Cancer · doi:10.1002/cncr.29778 · Cited by 142
Feedback inhibition by RALT controls signal output by the ErbB network
Anastasi, S., Fiorentino, L., Fiorini, M., Fraioli, R., Sala, G., Castellani, L., Alemà, S., Alimandi, M., & Segatto, O. (2003) · Oncogene · doi:10.1038/sj.onc.1206516 · Cited by 140
Bertuccio, P., Bosetti, C., Levi, F., Decarli, A., Negri, E., & Vecchia, C. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds652 · Cited by 140
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Self-citationGoeppert, B. F., Frauenschuh, L., Renner, M., Roessler, S. K., Stenzinger, A., Klauschen, F., Warth, A., Vogel, M. N., Mehrabi, A., Hafezi, M., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.206 · Cited by 136
Moehler, M. H., Maderer, A., Schimanski, C. C., Kanzler, S., Denzer, U. W., Kolligs, F. T., Ebert, M., Distelrath, A., Geißler, M., Trojan, J., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.09.013 · Cited by 136
Terada, T., Nakanuma, Y., & Sirica, A. E. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90229-5 · Cited by 133
Cell Lineage Tracing Reveals a Biliary Origin of Intrahepatic Cholangiocarcinoma
Guest, R. V., Boulter, L., Kendall, T. J., Minnis-Lyons, S. E., WALKER, R. E., Wigmore, S. J., Sansom, O. J., & Forbes, S. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1911 · Cited by 132
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
Miyamoto, M., Ojima, H., Iwasaki, M., Shimizu, H., Kokubu, A., Hiraoka, N., Kosuge, T., Yoshikawa, D., Kono, T., Furukawa, H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.199 · Cited by 129
Maisonneuve, C., Guilleret, I., Vick, P., Weber, T., Andre, P., Beyer, T., Blum, M., & Constam, D. B. (2009) · Development · doi:10.1242/dev.038174 · Cited by 129
Hsu, M., Sasaki, M., Igarashi, S., Sato, Y., & Nakanuma, Y. (2013) · Cancer · doi:10.1002/cncr.27955 · Cited by 125
Gao, Q., Zhao, Y., Wang, X., Guo, W., Gao, S., Wei, L., Shi, J.-Y., Shi, G., Wang, Z., Zhang, Y., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.062 · Cited by 125
El-Khoueiry, A. B., Rankin, C. J., Siegel, A. B., Iqbal, S., Gong, I.-Y., Micetich, K. C., Kayaleh, O. R., Lenz, H., & Blanke, C. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.801 · Cited by 123
The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma
Chung, J., Hong, S., Choi, B. Y., Cho, H., Yu, E., & Hewitt, S. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1084 · Cited by 123
Walter, T., Horgan, A. M., McNamara, M. G., McKeever, L., Min, T., Hedley, D. W., Serra, S., Krzyzanowska, M. K., Chen, E. X., MacKay, H. J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.003 · Cited by 119
Genomic insights into WNT/β-catenin signaling
Rosenbluh, J., Wang, X., & Hahn, W. C. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.007 · Cited by 119
Kaida, M., Morita‐Hoshi, Y., Soeda, A., Wakeda, T., Yamaki, Y., Kojima, Y., Ueno, H., Kondo, S., Morizane, C., Ikeda, M., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb65b9 · Cited by 118
MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer.
Yamamoto, K. T., Ueno, T., Kawaoka, T., Hazama, S., Fukui, M., Suehiro, Y., Hamanaka, Y., Ikematsu, Y., Imai, K., Oka, M., et al. (2005) · PubMed · Cited by 117
Altered Expression of β-Catenin without Genetic Mutation in Intrahepatic Cholangiocarcinoma
Sugimachi, K., Taguchi, K., Aishima, S., Tanaka, S., Shimada, M., Kajiyama, K., Sugimachi, K., & Tsuneyoshi, M. (2001) · Modern Pathology · doi:10.1038/modpathol.3880409 · Cited by 114
Lee, J. K., Capanu, M., O'Reilly, E. M., Ma, J., Chou, J. F., Shia, J., Katz, S. S., Gansukh, B., Reidy‐Lagunes, D. L., Segal, N. H., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.432 · Cited by 112
Santoro, A., Gebbia, V., Pressiani, T., Testa, A., Personeni, N., Bajardi, E. A., Foa, P., Buonadonna, A., Bencardino, K. B., Barone, C. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu576 · Cited by 111
Edeline, J., Bonnetain, F., Phelip, J., Watelet, J., Hammel, P. R., Joly, J., Abdelghani, M. B., Rosmorduc, O., Bouhier‐Leporrier, K., Jouve, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.225 · Cited by 110
Gwak, G., Yoon, J., Shin, C. M., Ahn, Y. J., Chung, J., Kim, Y. A., Kim, T., & Lee, H. S. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0016-1 · Cited by 108
Shen, D., Zhang, W., Zeng, X., & Liu, C. (2013) · Cancer Science · doi:10.1111/cas.12223 · Cited by 106
Wang, W., Zhong, W., Yuan, J., Yan, C., Hu, S., Tong, Y., Mao, Y., Hu, T., Zhang, B., & Song, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5514 · Cited by 105
Roa, I., de Toro, G., Schalper, K. A., de Aretxabala, X., Churi, C. R., & Javle, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 103
Paule, B., Herelle, M.-O., Rage, E., Ducreux, M. P., Adam, R. A., Guettier, C., & Bralet, M. (2007) · Oncology · doi:10.1159/000111117 · Cited by 102
Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer
Tsavaris, N. B., Kosmas, C., Gouveris, P., Gennatas, K., Polyzos, A., Mouratidou, D., Tsipras, H., Margaris, H., Papastratis, G., Tzima, E., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000011797.09549.53 · Cited by 100
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
Jensen, L. H., Lindebjerg, J., Pløen, J., Hansen, T. F., & Jakobsen, A. K. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds008 · Cited by 100
Ruzzenente, A., Fassan, M., Conci, S., Simbolo, M., Lawlor, R. T., Pedrazzani, C., Capelli, P., D’Onofrio, M., Iacono, C., Scarpa, A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5046-6 · Cited by 99
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Deshpande, V., Nduaguba, A. M., Zimmerman, S. M., Kehoe, S. M., MacConaill, L. E., Lauwers, G. Y., Ferrone, C. R., Bardeesy, N. M., Zhu, A. X., & Hezel, A. F. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-60 · Cited by 96
Self-citationA phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
Sohal, D. P. S., Mykulowycz, K., Uehara, T., Teitelbaum, U. R., Damjanov, N., Giantonio, B. J., Carberry, M., Wissel, P. S., Jacobs-Small, M., O'Dwyer, P. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt416 · Cited by 93
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract
Riener, M., Bawohl, M., Clavien, P., & Jochum, W. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20540 · Cited by 92
Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
Kobayashi, M., Sakabe, T., Abe, H., Tanii, M., Takahashi, H., Chiba, A., Yanagida, E., Shibamoto, Y., Ogasawara, M., Tsujitani, S., et al. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-013-2286-2 · Cited by 91
Tang, D., Nagano, H., Yamamoto, H., Wada, H., Nakamura, M., Kondo, M., Ôta, H., Yoshioka, S., Kato, H., Damdinsuren, B., et al. (2006) · Oncology Reports · doi:10.3892/or.15.3.525 · Cited by 88
Aruga, A., Takeshita, N., Kotera, Y., Okuyama, R., Matsushita, N., Ohta, T., Takeda, K., & Yamamoto, M. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-61 · Cited by 83
Ikenoue, T., Terakado, Y., Nakagawa, H., Hikiba, Y., Fujii, T., Matsubara, D., Noguchi, R., Zhu, C., Yamamoto, K., Kudo, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep23899 · Cited by 81
Settakorn, J., Kaewpila, N., Burns, G. F., & Leong, A. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.026575 · Cited by 80
Ahn, D. H., Li, J., Wei, L., Doyle, A., Marshall, J. L., Schaaf, L. J., Phelps, M. A., Villalona-Calero, M. A., & Bekaii‐Saab, T. (2015) · Scientific Reports · doi:10.1038/srep12122 · Cited by 80
Tokumoto, N., Ikeda, S., Ishizaki, Y., Kurihara, T., Ozaki, S., Iseki, M., Shimizu, Y., Itamoto, T., Arihiro, K., Okajima, M., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.4.973 · Cited by 79
Aruga, A., Takeshita, N., Kotera, Y., Okuyama, R., Matsushita, N., Ohta, T., Takeda, K., & Yamamoto, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3592 · Cited by 76
Bridgewater, J. A., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H. S., & Valle, J. W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2174-8 · Cited by 76
Self-citationLoregger, A., Grandl, M., Mejías‐Luque, R., Allgäuer, M., Degenhart, K., Haselmann, V., Oikonomou, C., Hatzis, P., Janssen, K., Nitsche, U., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac6757 · Cited by 75
Chiorean, E. G., Ramasubbaiah, R., Yu, M., Picus, J., Bufill, J. A., Tong, Y., Coleman, N., Johnston, E. L., Currie, C., & Loehrer, P. J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0253 · Cited by 74
Saetta, A. A., Papanastasiou, P., Michalopoulos, N., Gigelou, F., Korkolopoulou, P. A., Bei, T., & Patsouris, E. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1046-9 · Cited by 71
Liu, W., Chen, J., Hsu, C.-H., Li, Y.-H., Chen, Y., Lin, C.-Y. E., Huang, S.-J., Chang, Z.-K., Chen, Y., Lin, C.-H., et al. (2012) · Hepatology · doi:10.1002/hep.25914 · Cited by 69
Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun
Hibi, T., Itano, O., Shinoda, M., & Kitagawa, Y. (2016) · Surgery Today · doi:10.1007/s00595-016-1337-1 · Cited by 69
RNF43 interacts with NEDL1 and regulates p53-mediated transcription
Shinada, K., Tsukiyama, T., Sho, T., Okumura, F., Asaka, M., & Hatakeyama, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.082 · Cited by 68
Lee, D., Do, I., Choi, K., Sung, C. O., Jang, K., Choi, D.-W., Heo, J. S., Choi, S. H., Kim, J., Park, J. Y., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.133 · Cited by 62
Genetics of Opisthorchis viverrini-related cholangiocarcinoma
Jusakul, A., Kongpetch, S., & Teh, B. T. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000162 · Cited by 59
Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma
Momoi, H., Itoh, T., Nozaki, Y., Arima, Y., Okabe, H., Satoh, S., Toda, Y., Sakai, E., Nakagawara, K.-I., Flemming, P., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00106-4 · Cited by 57
GNAS Mutations Identify a Set of Right-Sided, RAS Mutant, Villous Colon Cancers
Fecteau, R. E., Lutterbaugh, J., Markowitz, S. D., Willis, J. E., & Guda, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087966 · Cited by 56
Javle, M. M., Shroff, R. T., Zhu, A. X., Sadeghi, S., Choo, S., Borad, M. J., Lowery, M. A., El-Khoueiry, A. B., Macarulla, T. M., Philip, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.335 · Cited by 55
Self-citationHedgehog signaling pathway is a potential therapeutic target for gallbladder cancer
Matsushita, S., Onishi, H., Nakano, K., Nagamatsu, I., Imaizumi, A., Hattori, M., Oda, Y., Tanaka, M., & Katano, M. (2014) · Cancer Science · doi:10.1111/cas.12354 · Cited by 54
Tang, L., Tan, Y., Jiang, B., Pan, Y., Li, S.-X., Yang, G.-Z., Wang, M., Wang, Q., Zhang, J., Zhou, W., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0349 · Cited by 54
Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies
Marks, E. I. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i11.338 · Cited by 54
Heinrich, S., & Clavien, P. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283378eb0 · Cited by 52
Yoshitomi, M., Yutani, S., Matsueda, S., Ioji, T., Komatsu, N., Shichijo, S., Yamada, A., Itoh, K., Sasada, T., & Kinoshita, H. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.424 · Cited by 51
Ballarò, C., Ceccarelli, S., Tiveron, C., Tatangelo, L., Salvatore, A. M., Segatto, O., & Alemà, S. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400458 · Cited by 47
Cholangiocarcinoma: risk factors and clinical presentation.
Gatto, M., & Alvaro, D. (2010) · PubMed · Cited by 44
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma
Fingas, C. D., Mertens, J. C., Razumilava, N., Sydor, S., Bronk, S. F., Christensen, J. D., Rizvi, S. H., Canbay, A. E., Treckmann, J. W., Paul, A., et al. (2013) · Hepatology · doi:10.1002/hep.26484 · Cited by 41
Zhang, L., Jiang, L., Sun, Q., Peng, T., Lou, K., Liu, N., & Leng, J. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9523-5 · Cited by 39
Shirabe, K., Shimada, M., Tsujita, E., Aishima, S.-I., Maehara, S., Tanaka, S., Takenaka, K., & Maehara, Y. (2004) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2003.12.044 · Cited by 36
Lamarca, Á., Benafif, S., Ross, P. J., Bridgewater, J. A., & Valle, J. W. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.018 · Cited by 34
Self-citationSuder, A., Ang, J. E., Kyle, F. J., Harris, D., Rudman, S. M., Kristeleit, R. S., Solca, F., Uttenreuther‐Fischer, M., Pemberton, K., Pelling, K., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.041 · Cited by 30
Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues
Zhu, A. X., & Knox, J. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0432 · Cited by 28
Self-citationClinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma
Lee, K.-H., Lee, K.-B., Kim, T.-Y., Han, S.-W., Oh, D.-Y., Im, S., Kim, T.-Y., Yi, N.-J., Lee, K.-W., Suh, K.-S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1737-4 · Cited by 24
Chen, W., Liang, J., Huang, L.-P., Cai, J., Lei, Y., Lai, J., Liang, L., & Zhang, K. (2016) · European Journal of Histochemistry · doi:10.4081/ejh.2016.2536 · Cited by 24
IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications
Borger, D. R., & Zhu, A. X. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.32 · Cited by 23
Self-citationAnimal models of cholangiocarcinoma
Ko, K. S., Peng, J. W., & Yang, H. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835d6a3e · Cited by 19
Expression of DPC4/Smad4 gene in stone‐containing intrahepatic bile duct
Lee, K., Chang, W., Wang, S., Chuang, S., Chai, C., & Hu, S. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20517 · Cited by 16
Hong, D. S., Brose, M. S., Doebele, R. C., Shaw, A. T., Dowlati, A., Bauer, T. M., Farago, A. F., Estrada‐Bernal, A., Lee, A. T., Cox, M. C., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-pr13 · Cited by 14
Săftoiu, A., Bhutani, M. S., Vilmann, P., Şurlin, V., Uthamanthil, R. K., Lee, J. H., Bektas, M., Singh, H., Gheonea, D. I., Pătraşcu, Ş., et al. (2011) · Hepatogastroenterology · doi:10.5754/hge11744 · Cited by 14
Financial and work related impact of cancer in young adult (YA) survivors.
Baker, K. S., Ambrose, K., Arvey, S. R., Casillas, J., Ganz, P. A., Jacobs, L. A., McCabe, M. S., Overholser, L., Partridge, A. H., Rajotte, E. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.3_suppl.15 · Cited by 13
Mazzaferro, V., Shaib, W. L., Rimassa, L., Harris, W. P., Personeni, N., El‐Rayes, B. F., Tolcher, A. W., Hall, T., Wang, Y., Schwartz, B. E., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw200.19 · Cited by 12
Eads, J. R., Goyal, L., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Landau, S. B., & Sirard, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e15603 · Cited by 10
Self-citation
Cited by
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Self-citationPiha‐Paul, S. A., Oh, D., Ueno, M., Malka, D., Chung, H. C., Nagrial, A., Kelley, R. K., Ros, W., Italiano, A., Nakagawa, K., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33013 · Cited by 486
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., Hainsworth, J., Meric-Bernstam, F., Swanton, C., Sweeney, C. J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00336-3 · Cited by 425
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 412
Self-citation
Metadata
- Authors
- Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X.
- Venue
- Cancer Discovery
- Published
- 2017-08-31
- Volume
- 7
- Issue
- 9
- Pages
- 943-962
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2745824859
- Cited by
- 626
- References
- 186
- FWCI
- 41.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.